drugset / Trial / NCT05642312

A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema

NCT05642312

Phase 3 Completed 245 enrolled Hoffmann-La Roche
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.

Timeline

Start
2023-01-09
Primary completion
2024-12-09
Completion
2025-07-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Vamikibart Monoclonal antibody Intravitreal

Indications